{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR+Positive+Solid+Tumor&page=2", "query": { "condition": "EGFR Positive Solid Tumor", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR+Positive+Solid+Tumor&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T03:10:08.841Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05985655", "title": "Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Pancreatic Adenocarcinoma", "Non-small Cell Lung Cancer (NSCLC)", "Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)", "Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "GTAEXS617", "type": "DRUG" }, { "name": "SoC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2023-07-06", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-05-22T03:10:08.841Z", "location_count": 4, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • San Antonio, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05985655" }, { "nct_id": "NCT06414733", "title": "HER-2 B Cell Peptide Vaccine", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "Metastatic Gastrointestinal Carcinoma", "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "EGFR Overexpression" ], "interventions": [ { "name": "Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pravin T.P Kaumaya", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2025-01-17", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2025-08-24", "last_synced_at": "2026-05-22T03:10:08.841Z", "location_count": 1, "location_summary": "Indianpolis, Indiana", "locations": [ { "city": "Indianpolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06414733" }, { "nct_id": "NCT03175224", "title": "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors", "Advanced Cancer", "Renal Cancer", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "NSCLC", "Lung Cancer", "Brain Tumor", "Glioblastoma Multiforme", "EGFR Gene Mutation", "MET Amplification", "HGF", "Thyroid Cancer", "Pancreatic Cancer", "Colon Cancer", "MET Alteration", "MET Fusion", "Exon 14 Skipping" ], "interventions": [ { "name": "APL-101 Oral Capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apollomics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 497, "start_date": "2017-09-27", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-05-22T03:10:08.841Z", "location_count": 6, "location_summary": "Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03175224" }, { "nct_id": "NCT02729298", "title": "First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "EGFR Positive Non-small Cell Lung Cancer", "Colorectal Carcinoma", "Recurrent Ovarian Carcinoma", "BRAF-Mutated Melanoma" ], "interventions": [ { "name": "TP-0903", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2016-12-14", "completion_date": "2022-06-29", "has_results": false, "last_update_posted_date": "2023-11-14", "last_synced_at": "2026-05-22T03:10:08.841Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Denver, Colorado + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02729298" }, { "nct_id": "NCT04225117", "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Malignant Solid Tumors" ], "interventions": [ { "name": "enfortumab vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2020-03-10", "completion_date": "2026-09-30", "has_results": true, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-22T03:10:08.841Z", "location_count": 29, "location_summary": "Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04225117" }, { "nct_id": "NCT03740256", "title": "Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Head and Neck Squamous Cell Carcinoma", "Cancer of the Salivary Gland", "Lung Cancer", "Breast Cancer", "Gastric Cancer", "Esophageal Cancer", "Colorectal Cancer", "Pancreatic Adenocarcinoma", "Solid Tumor" ], "interventions": [ { "name": "CAdVEC", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2020-12-14", "completion_date": "2038-12-30", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-05-22T03:10:08.841Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03740256" }, { "nct_id": "NCT03319459", "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Positive Gastric Cancer", "Colorectal Cancer", "Head and Neck Squamous Cell Carcinoma", "EGFR Positive Solid Tumor", "Advanced Solid Tumors", "HER2-positive Breast Cancer", "Hepatocellular Carcinoma", "Non Small Cell Lung Cancer", "Renal Cell Carcinoma", "Pancreatic Cancer", "Melanoma" ], "interventions": [ { "name": "FATE-NK100", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2018-01-18", "completion_date": "2020-12-15", "has_results": false, "last_update_posted_date": "2021-11-22", "last_synced_at": "2026-05-22T03:10:08.841Z", "location_count": 4, "location_summary": "San Diego, California • Minneapolis, Minnesota • Columbus, Ohio + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03319459" }, { "nct_id": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma", "Gastric Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma", "EGFR Positive Solid Tumor", "HER2-positive Breast Cancer", "Hepatocellular Carcinoma", "Small Cell Lung Cancer", "Renal Cell Carcinoma", "Pancreas Cancer", "Melanoma", "NSCLC", "Urothelial Carcinoma", "Cervical Cancer", "Microsatellite Instability", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "FT500", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2019-02-15", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2023-05-01", "last_synced_at": "2026-05-22T03:10:08.841Z", "location_count": 4, "location_summary": "San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03841110" }, { "nct_id": "NCT04872166", "title": "A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Breast Cancer" ], "interventions": [ { "name": "BTX-A51", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Edgewood Oncology Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2021-06-07", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-01-30", "last_synced_at": "2026-05-22T03:10:08.841Z", "location_count": 6, "location_summary": "Lake Mary, Florida • Sarasota, Florida • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Lake Mary", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04872166" }, { "nct_id": "NCT03284723", "title": "PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "PF-06804103", "type": "DRUG" }, { "name": "PF-06804103 + Palbociclib +Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2017-11-01", "completion_date": "2021-08-31", "has_results": true, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-05-22T03:10:08.841Z", "location_count": 26, "location_summary": "Tucson, Arizona • Los Angeles, California • Santa Monica, California + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03284723" } ] }